Quick Read – JNJ holds an AAA S&P credit rating, which is higher than the U.S. government’s AA+, backing 64 consecutive years of dividend increases. – TREMFYA surged 68%, CARVYKTI jumped 62%, and DARZALEX grew 22% in Q1 2026, more than offsetting a 60% STELARA biosimilar…
llapse. – CEO Joaquin Duato raised full-year revenue guidance to between $100B and $101B after Q1 2026 beat estimates for the fourth consecutive quarter. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today
Johnson & Johnson (NYSE:JNJ) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sovereign bond while still compounding capital. Healthcare is the one expense Americans cannot defer, and Johnson & Johnson sits at the center of how that spending gets delivered. Pillar 1: Durability That Outlasts CEOs and Cycles The post-Kenvue Johnson & Johnson is a focused operator across two engines: Innovative Medicine, which generated $15.43 billion in Q1 2026 (+11.2%), and MedTech at $8.64 billion (+7.7%).
Revenue is spread across six priority areas, including Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision, so no single product failure can break the company. Growth drivers like DARZALEX ($3.96 billion, +22.5%), TREMFYA (+68.3%), and CARVYKTI (+62.1%) are doing the heavy lifting while the pipeline (IMAAVY, nipocalimab, OTTAVA robotic surgery) refills the bench. Geographic balance reinforces it: U.S. revenue rose 8.3% while Rest of World rose 11.9%.